Merck moves forward with Vioxx successor

Drugmaker Merck & Co. on Wednesday gave preliminary results of a study of its investigational painkiller Arcoxia, the planned successor to Vioxx, which was pulled off the market in 2004 after being linked to stroke and heart attack.

Merck said the study, comparing Arcoxia with the anti-inflammatory drug diclofenac, found the “relative risk” of certain cardiovascular events was similar.

The incidence of patients withdrawing from the study due to side effects related to high blood pressure, edema and congestive heart failure was significantly higher for Arcoxia than for diclofenac, it said.

The U.S. Food and Drug Administration, rather than approve the Arcoxia outright, had sent Merck an “approvable letter” seeking more information on the drug.

Vioxx was pulled off the market in 2004 after findings that it doubled the risk of heart attack and stroke, leading Merck shares to sink and resulting in thousands of lawsuits against the company.

Print Version
Tell-a-Friend comments powered by Disqus

RELATED ARTICLES:

FDA denies approval to wider use of J&J’s blood clot preventer   FDA Warns of Potential Risk of Severe Liver Injury With Use of Dronedarone   Statin label to carry diabetes warning   A mobile device for preventing and treating drug use   White House announces plans to reduce prescription drug abuse   Vioxx harmful even after patients stopped taking it   Diabetes drugs warning: they cause heart problems   FDA warns against fake online H1N1 remedy claims   Row brews over ecstasy downgrade call   FDA lacks access to food safety records: Congress   Man says prescription drug caused gambling problem   Rash most common side effect in Vectibix trials